Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | OSTX |
---|---|---|
09:32 ET | 2050 | 3.72 |
09:41 ET | 391 | 3.75 |
09:45 ET | 500 | 3.675 |
09:48 ET | 1635 | 3.7135 |
09:54 ET | 100 | 3.6675 |
09:56 ET | 300 | 3.66 |
09:57 ET | 208 | 3.67 |
10:08 ET | 308 | 3.704 |
10:14 ET | 1000 | 3.6575 |
10:28 ET | 100 | 3.7066 |
10:30 ET | 270 | 3.71 |
10:46 ET | 561 | 3.65 |
10:53 ET | 250 | 3.69 |
10:55 ET | 1900 | 3.65 |
10:57 ET | 1140 | 3.65 |
11:00 ET | 400 | 3.6999 |
11:02 ET | 1324 | 3.67 |
11:04 ET | 999 | 3.64 |
11:06 ET | 111 | 3.68 |
11:11 ET | 543 | 3.644 |
12:00 ET | 140 | 3.65 |
12:07 ET | 144 | 3.694 |
12:12 ET | 146 | 3.64 |
12:21 ET | 249 | 3.7 |
01:10 ET | 100 | 3.67 |
01:26 ET | 200 | 3.63 |
01:50 ET | 169 | 3.645 |
01:53 ET | 600 | 3.65 |
01:55 ET | 492 | 3.6 |
02:00 ET | 1000 | 3.63 |
02:02 ET | 186 | 3.6 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
OS Therapies Inc | 70.4M | -12.0x | --- |
enVVeno Medical Corp | 69.7M | -3.7x | --- |
Connect Biopharma Holdings Ltd | 69.6M | -3.2x | --- |
Vivani Medical Inc | 69.1M | -2.7x | --- |
Boundless Bio Inc | 68.3M | -1.2x | --- |
Vor Biopharma Inc | 72.5M | -0.6x | --- |
OS Therapies Incorporated is a clinical-stage biopharmaceutical company. The Company is focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. It built a pipeline of product candidates targeting multiple indications for solid cancers. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. OST-HER2 is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH sensitive silicone linkers (SiLinkers). The payloads can include antibodies, chemotherapeutics, cytotoxins and potentially mRNA treatments directly into and in the vicinity of solid tumors.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $70.4M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 20.0M |
OS Therapies Inc does not pay a dividend. | |
Beta | --- |
EPS | $-0.30 |
Book Value | $-1.17 |
P/E Ratio | -12.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.